HRP20210749T1 - Farmaceutski pripravci koji sadrže azd9291 - Google Patents
Farmaceutski pripravci koji sadrže azd9291 Download PDFInfo
- Publication number
- HRP20210749T1 HRP20210749T1 HRP20210749TT HRP20210749T HRP20210749T1 HR P20210749 T1 HRP20210749 T1 HR P20210749T1 HR P20210749T T HRP20210749T T HR P20210749TT HR P20210749 T HRP20210749 T HR P20210749T HR P20210749 T1 HRP20210749 T1 HR P20210749T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutical
- parts
- pharmaceutical preparation
- preparation according
- diluents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1400034.3A GB201400034D0 (en) | 2014-01-02 | 2014-01-02 | Pharmaceutical Compositions comprising AZD9291 |
| PCT/GB2015/050001 WO2015101791A1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
| EP15700082.9A EP3089741B1 (en) | 2014-01-02 | 2015-01-02 | Pharmaceutical compositions comprising azd9291 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210749T1 true HRP20210749T1 (hr) | 2021-06-25 |
Family
ID=50191689
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210749TT HRP20210749T1 (hr) | 2014-01-02 | 2015-01-02 | Farmaceutski pripravci koji sadrže azd9291 |
Country Status (37)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
| NO2699580T3 (enExample) | 2014-01-24 | 2018-02-24 | ||
| SG11201809751XA (en) | 2016-05-26 | 2018-12-28 | Zeno Royalties & Milestones Llc | Egfr inhibitor compounds |
| CN108057036B (zh) * | 2016-11-07 | 2023-06-13 | 正大天晴药业集团股份有限公司 | 一种egfr抑制剂的固体药物组合物 |
| CN107176954B (zh) * | 2017-06-02 | 2019-01-11 | 无锡双良生物科技有限公司 | 一种egfr抑制剂的药用盐及其晶型、制备方法和应用 |
| CN110013468B (zh) * | 2018-01-09 | 2022-02-18 | 北京福元医药股份有限公司 | 一种azd9291氘代衍生物药物制剂 |
| WO2019138346A1 (en) * | 2018-01-10 | 2019-07-18 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of osimertinib |
| TW201941773A (zh) * | 2018-02-12 | 2019-11-01 | 瑞典商阿斯特捷利康公司 | 用於治療非小細胞肺癌之奧希替尼 |
| PL3758708T3 (pl) * | 2018-03-01 | 2025-03-31 | Astrazeneca Ab | Kompozycje farmaceutyczne zawierające (2s)-{(1s)-1-cyjano-2-[4-(3-metylo-2-okso-2,3-dihydro-1,3-benzoksazol-5-ilo)fenylo]etylo}-1,4-oksazepano-2-karboksyamid |
| WO2019178868A1 (zh) | 2018-03-23 | 2019-09-26 | 无锡双良生物科技有限公司 | 一种药物组合物及其制备方法和用途 |
| EP3823627A4 (en) | 2018-07-17 | 2022-04-20 | Insmed Incorporated | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF LUPUS ENEHROPATHY |
| KR20200043618A (ko) | 2018-10-18 | 2020-04-28 | 주식회사유한양행 | 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물 |
| MX2021011810A (es) | 2019-03-29 | 2021-10-26 | Astrazeneca Ab | Osimertinib para su uso en el tratamiento de cancer de pulmon de celulas no peque?as. |
| US20210161897A1 (en) | 2019-11-12 | 2021-06-03 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| AU2021211871A1 (en) | 2020-01-20 | 2022-09-08 | Astrazeneca Ab | Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer |
| US20210369709A1 (en) | 2020-05-27 | 2021-12-02 | Astrazeneca Ab | EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER |
| TW202304457A (zh) * | 2021-03-22 | 2023-02-01 | 瑞典商阿斯特捷利康公司 | 配製物 |
| IL315848A (en) | 2022-03-31 | 2024-11-01 | Astrazeneca Ab | Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in combination with an AKT inhibitor for cancer treatment |
| CA3249080A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| US20240116926A1 (en) | 2022-04-28 | 2024-04-11 | Astrazeneca Ab | Heteroaromatic compounds |
| WO2023209090A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their application in the treatment of cancer |
| WO2023209088A1 (en) | 2022-04-28 | 2023-11-02 | Astrazeneca Ab | Bicyclic heteroaromatic compounds and their use in the treatment of cancer |
| KR20250029133A (ko) | 2022-06-27 | 2025-03-04 | 아스트라제네카 아베 | 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제를 포함하는 조합물 |
| CN119654152A (zh) | 2022-07-08 | 2025-03-18 | 阿斯利康(瑞典)有限公司 | 与hgf-受体抑制剂组合用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| WO2025092926A1 (zh) * | 2023-10-31 | 2025-05-08 | 浙江同源康医药股份有限公司 | 一种嘧啶类衍生物的药物组合物 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL110376A (en) * | 1993-08-02 | 1998-08-16 | Bristol Myers Squibb Co | Pharmaceutical compositions containing ifetroban salts and methods for the preparation thereof |
| SE9802973D0 (sv) * | 1998-09-03 | 1998-09-03 | Astra Ab | Immediate release tablet |
| WO2001076565A1 (fr) * | 2000-04-12 | 2001-10-18 | Banyu Pharmaceutical Co., Ltd. | Compositions et preparations se desintegrant dans la cavite buccale |
| US6881737B2 (en) | 2001-04-11 | 2005-04-19 | Amgen Inc. | Substituted triazinyl acrylamide derivatives and methods of use |
| KR101002374B1 (ko) | 2002-02-26 | 2010-12-17 | 아스트라제네카 아베 | 수용성 셀룰로스 유도체를 포함하는 이레사의 약학 조제물 |
| US20080102133A1 (en) * | 2004-10-05 | 2008-05-01 | Antje Brueck-Scheffler | Oral Pharmaceutical Preparation for Proton Pump Antagonists |
| ES2279715B1 (es) * | 2005-12-26 | 2008-06-01 | Laboratorios Lesvi, S.L. | Formulacion oral de olanzapina. |
| TW200800181A (en) * | 2006-02-09 | 2008-01-01 | Sankyo Co | Pharmaceutical composition for anticancer |
| JP5576922B2 (ja) * | 2006-04-20 | 2014-08-20 | 信越化学工業株式会社 | 腸溶性固体分散体を含んでなる固形製剤 |
| EP2170062A4 (en) * | 2007-07-12 | 2010-12-29 | Tragara Pharmaceuticals Inc | METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER DISORDERS, TUMORS AND TUMOR-DISORDED DISEASES |
| WO2012139736A1 (en) | 2011-04-11 | 2012-10-18 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition comprising bosentan |
| KR101317809B1 (ko) | 2011-06-07 | 2013-10-16 | 한미약품 주식회사 | 암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물 |
| PT3009431T (pt) * | 2011-07-27 | 2017-12-26 | Astrazeneca Ab | Compostos de 2-(2,4,5-anilino-substituídos)pirimidina como moduladores úteis do egfr para o tratamento do cancro |
| ES2946549T3 (es) * | 2012-01-13 | 2023-07-20 | Xspray Pharma Ab Publ | Composición farmacéutica de nilotinib |
| WO2013160916A1 (en) | 2012-04-25 | 2013-10-31 | Hetero Research Foundation | Sunitinib malate solid dispersion |
| GB201400034D0 (en) * | 2014-01-02 | 2014-02-19 | Astrazeneca Ab | Pharmaceutical Compositions comprising AZD9291 |
-
2014
- 2014-01-02 GB GBGB1400034.3A patent/GB201400034D0/en not_active Ceased
- 2014-12-29 AR ARP140104947A patent/AR098989A1/es not_active Application Discontinuation
- 2014-12-29 UY UY0001035933A patent/UY35933A/es not_active Application Discontinuation
- 2014-12-31 TW TW103146652A patent/TWI702953B/zh active
-
2015
- 2015-01-02 MY MYPI2016702433A patent/MY183536A/en unknown
- 2015-01-02 CA CA2933403A patent/CA2933403C/en active Active
- 2015-01-02 PH PH1/2016/501310A patent/PH12016501310B1/en unknown
- 2015-01-02 US US15/109,170 patent/US10183020B2/en active Active
- 2015-01-02 AU AU2015204218A patent/AU2015204218B2/en active Active
- 2015-01-02 NZ NZ721298A patent/NZ721298A/en unknown
- 2015-01-02 HR HRP20210749TT patent/HRP20210749T1/hr unknown
- 2015-01-02 EP EP15700082.9A patent/EP3089741B1/en active Active
- 2015-01-02 PE PE2016000943A patent/PE20161170A1/es unknown
- 2015-01-02 JP JP2016544368A patent/JP6588915B2/ja active Active
- 2015-01-02 PT PT157000829T patent/PT3089741T/pt unknown
- 2015-01-02 CN CN201580003266.4A patent/CN105848647B/zh active Active
- 2015-01-02 RS RS20210698A patent/RS61927B1/sr unknown
- 2015-01-02 CR CR20160310A patent/CR20160310A/es unknown
- 2015-01-02 MX MX2016008744A patent/MX367358B/es active IP Right Grant
- 2015-01-02 KR KR1020167020731A patent/KR102336378B1/ko active Active
- 2015-01-02 SM SM20210330T patent/SMT202100330T1/it unknown
- 2015-01-02 LT LTEP15700082.9T patent/LT3089741T/lt unknown
- 2015-01-02 CN CN202210324141.3A patent/CN114712362A/zh active Pending
- 2015-01-02 DK DK15700082.9T patent/DK3089741T3/da active
- 2015-01-02 WO PCT/GB2015/050001 patent/WO2015101791A1/en not_active Ceased
- 2015-01-02 PL PL15700082T patent/PL3089741T3/pl unknown
- 2015-01-02 HU HUE15700082A patent/HUE054344T2/hu unknown
- 2015-01-02 ES ES15700082T patent/ES2873226T3/es active Active
- 2015-01-02 EA EA201691242A patent/EA034243B9/ru not_active IP Right Cessation
- 2015-01-02 SI SI201531610T patent/SI3089741T1/sl unknown
- 2015-01-02 SG SG11201605339QA patent/SG11201605339QA/en unknown
-
2016
- 2016-06-13 IL IL246186A patent/IL246186B/en active IP Right Grant
- 2016-06-22 DO DO2016000156A patent/DOP2016000156A/es unknown
- 2016-06-22 CL CL2016001609A patent/CL2016001609A1/es unknown
- 2016-06-29 GT GT201600142A patent/GT201600142A/es unknown
- 2016-07-01 NI NI201600098A patent/NI201600098A/es unknown
- 2016-08-01 ZA ZA2016/05300A patent/ZA201605300B/en unknown
-
2018
- 2018-11-20 US US16/196,185 patent/US20190111057A1/en not_active Abandoned
-
2020
- 2020-08-04 US US16/984,276 patent/US20200360378A1/en not_active Abandoned
-
2021
- 2021-06-08 CY CY20211100499T patent/CY1124848T1/el unknown
- 2021-09-17 US US17/478,117 patent/US20240189310A1/en not_active Abandoned
-
2022
- 2022-04-26 US US17/729,162 patent/US20220395502A1/en not_active Abandoned
-
2024
- 2024-09-26 US US18/897,609 patent/US20250017930A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210749T1 (hr) | Farmaceutski pripravci koji sadrže azd9291 | |
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20160135T1 (hr) | Derivati 2-(2,4,5-supstituiranog-anilino) pirimidina kao modulatori egfr koji su korisni za lijeäśenje raka | |
| HRP20221263T1 (hr) | Ciklički di-nukleotidni spojevi i postupci uporabe | |
| HRP20221294T1 (hr) | Neuroaktivni steroidi, njihovi pripravci i uporabe | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| JP2015078230A5 (enExample) | ||
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| HUE052332T2 (hu) | Heteroaril-származék vagy gyógyászatilag elfogadható sója, eljárás annak elõállítására, és az ezeket hatóanyagént tartalmazó gyógyászati készítmény PI3 kinázokkal összefüggõ betegségek megelõzésére vagy kezelésére | |
| HRP20240231T1 (hr) | Farmaceutske formulacije inhibitora brutonove tirozin kinaze | |
| JP2015038135A5 (enExample) | ||
| JP2014218522A5 (enExample) | ||
| HRP20211278T1 (hr) | Supstituirani derivati indolina kao inhibitori replikacije denga virusa | |
| JP2017516848A5 (enExample) | ||
| HRP20220683T1 (hr) | Liječenje parkinsonove bolesti | |
| JP2017516847A5 (enExample) | ||
| JP2016525548A5 (enExample) | ||
| EP3400964A4 (en) | TASTE-MASKED AND ORAL ADMINISTRATIVE PHARMACEUTICAL PREPARATION WITH VARENICLIN OR PHARMACEUTICAL SALT OF IT | |
| MY206893A (en) | Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof | |
| JP2018532806A5 (enExample) | ||
| HRP20211107T1 (hr) | Mimetici obrambenih proteina domaćina, namijenjeni profilaksi i/ili liječenju upalnih bolesti gastrointestinalnog sustava | |
| HRP20191050T1 (hr) | Pripravak protiv virusnog konjunktivitisa koji sadrži jota-karagenan | |
| WO2018234871A3 (en) | COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE |